Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?

详细信息    查看全文

• 作者：Massimo Franchini^a ; ^{massimo.franchini@asst-mantova.it} ; Giuseppe Lippi^b
• 关键词：Inhibitor ; Alloantibody hemophilia A ; Prevention
• 刊名：Thrombosis Research
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：148
• 期：Complete
• 页码：96-100
• 全文大小：241 K
• 卷排序：148

文摘

The development of FVIII inhibitors is the most challenging complication of replacement therapy in hemophilia A. The development of FVIII alloantibodies is a multifactorial process which involves genetic and acquired risk factors. Among the non-genetic risk factors, an early intensive treatment carries the greater inhibitor risk.